SPORE IN BREAST CANCER

乳腺癌孢子将大大加强和扩大UAB综合癌症中心的乳腺癌研究，重点是转化研究。它的主题是化学预防、基因治疗、靶向免疫治疗、抗血管生成、肿瘤发生的遗传机制和他莫昔芬耐药机制都是国家重点研究领域。6个研究项目涉及跨学科研究团队，包括：1)“新型类维生素a的临床前/临床开发”提供UAB设计试剂的药物化学、临床前毒理学/疗效和早期临床研究；2)“激素抵抗：机制和逆转”探讨了诱导他莫昔芬耐药的机制以及抗血管生成药物在逆转这一过程中的作用；3)“一种新型乳腺癌致癌基因GKLF的生物学和中间标志物作用”将探讨GKLF过表达导致的致癌机制及其在化学预防试验中作为中间标志物的潜力；4)“针对肿瘤血管的基因治疗”将开发针对乳腺癌血管的新型腺病毒载体，作为抗血管生成策略的介质；5)《乳腺癌多核苷酸疫苗治疗》将设计增强肿瘤抗原DNA疫苗诱导动物模型和患者抗肿瘤免疫的方法；6)“转移性乳腺癌的预靶向放射免疫治疗”，利用单链抗体和链亲和素组成的新型融合蛋白将生物素- dota放射性同位素定位到肿瘤部位。在动物模型和病人中。这些项目将由三个核心支持：1)行政/生物统计；2)组织资源与免疫病理；3)临床试验。此外，SPORE将有一个针对乳腺癌转化研究的职业发展计划（5个奖项）和一个发展研究计划（每年5-6个试点项目）。孢子有很强的机构承诺和热情的计划与其他孢子互动，包括我们自己的卵巢癌孢子。这个孢子将增加科学发现，并迅速将资金转化为创新的临床试验。

The Breast Cancer SPORE will greatly strengthen and expand the breast cancer research of the UAB Comprehensive Cancer Center with an emphasis on translational research. It's themes of Chemoprevention, Gene Therapy, Targeted Immunotherapy, Anti-angiogenesis, Genetic Mechanisms of Oncogenesis, and Mechanisms of Tamoxifen Resistance are all national priority areas. Six research projects involve interdisciplinary investigative teams including: 1) "Preclinical/Clinical Development of Novel Retinoids" provides medicinal chemistry, preclinical toxicology/efficacy and early clinical study of UAB designed reagents; 2) "Hormonal Resistance: Mechanisms and Reversal" explores the mechanisms which induce Tamoxifen resistance and the role of anti- angiogenesis agents in reversal of this process; 3) "Biology and Intermediate Marker Role of a Novel Breast Cancer Oncogene, GKLF" will explore the oncogenic mechanisms resulting from GKLF over- expression and its potential as an intermediate marker in chemoprevention trials; 4) "Gene Therapy Specifically Directed at Tumor Vasculature" will develop novel adenoviral vectors targeted to breast cancer vasculature as mediators of anti-angiogenesis strategies; 5) Polynucleotide Vaccine Therapy of Breast Cancer" will design methods to enhance tumor antigen DNA vaccine induction of anti-tumor immunity in animal models and patients; and 6) "Pre-targeting Radioimmunotherapy of Metastatic Breast Cancer" which will utilize a novel fusion protein composed of single chain antibodies and streptavidin to localize Biotin-DOTA-radioactive isotopes to tumor sites. in animal models and patients. These projects will be supported by three Cores: 1) Administrative/Biostatistics; 2) Tissue Resource and Immunopathology; and 3) Clinical Trials. In addition, the SPORE will have a Career Development Program directed at careers in Breast Cancer Translational Research (5 awards) and a Developmental Research Program (5-6 pilot projects annually). The SPORE has strong institutional commitments and enthusiastic plans for interaction with other SPOREs including our own Ovarian Cancer SPORE. This SPORE will increase scientific discoveries and rapidly translate fundings into innovative clinical trials.